Journal ArticleDOI
Site-specifically biotinylated VEGF(121) for near-infrared fluorescence imaging of tumor angiogenesis.
TLDR
An Avi-tagged VEGF(121) protein is developed, which is site-specifically biotinylated in the presence of bacterial BirA biotin ligase, which retains high affinity for VEGFR in vitro and allows receptor specific targeting in vivo in a 67NR murine xenograft model.Abstract:
The vascular endothelial growth factor (VEGF)/VEGF receptor (VEGFR) pathway is considered to be one of the most important regulators of angiogenesis and a key target in anticancer treatment. Imaging VEGFR expression can serve as a new paradigm for assessing the efficacy of antiangiogenic cancer therapy, improving cancer management, and elucidating the role and modulation of VEGF/VEGFR signaling during cancer development and intervention. In this study we developed an Avi-tagged VEGF(121) protein, which is site-specifically biotinylated in the presence of bacterial BirA biotin ligase. BirA biotinylated VEGF(121)-Avi (VEGF(121)-Avib) forms a stable complex with streptavidin-IRDye800 (SA800) that retains high affinity for VEGFR in vitro and allows receptor specific targeting in vivo in a 67NR murine xenograft model. In contrast, chemical coupling of IRDye800 abrogated the VEGFR binding ability of the modified protein both in vitro and in vivo. The VEGF(121)-Avib/SA800 complex (VEGF-Avib/SA800) may be used for quantitative and repetitive near-infrared fluorescence imaging of VEGFR expression and translated into clinic for evaluating cancer and other angiogenesis related diseases.read more
Citations
More filters
Journal ArticleDOI
Molecular imaging of VEGF in gastrointestinal cancer in vivo using confocal laser endomicroscopy
Sebastian Foersch,Ralf Kiesslich,Maximillian J Waldner,Peter G. Delaney,Peter R. Galle,Markus F. Neurath,Martin Goetz +6 more
TL;DR: In vivo molecular imaging with specific targeting of VEGF is possible in murine tumours, human xenografts and tissue specimens using Confocal laser endomicroscopy, and is transferable to stratification of patients with CRC during endoscopy even today.
Journal ArticleDOI
VEGF121-Conjugated Mesoporous Silica Nanoparticle: A Tumor Targeted Drug Delivery System
Shreya Goel,Feng Chen,Hao Hong,Hector F. Valdovinos,Reinier Hernandez,Sixiang Shi,Todd E. Barnhart,Weibo Cai +7 more
TL;DR: It is demonstrated that a significantly higher amount of sunitinib could be delivered to the U87MG tumor by targeting VEGFR when compared with the non-targeted counterparts.
Journal ArticleDOI
Prognostic significance and potential therapeutic target of VEGFR2 in hepatocellular carcinoma
TL;DR: There was a correlation of high VEGFR2 expression with prognostic significance in HCC and the self-made anti-VEGFR2 monoclonal antibody could be used for future anti-HCC-targeted therapy research.
Journal ArticleDOI
Non-invasive imaging for studying anti-angiogenic therapy effects
TL;DR: In this paper, the authors discuss tools and methods to image tumour angiogenesis and monitor anti-angiogenic therapy effects using contrastenhanced ultrasound (US) and magnetic resonance imaging (MRI).
Journal ArticleDOI
Imaging key biomarkers of tumor angiogenesis.
TL;DR: Molecular imaging of longitudinal responses to anti-angiogenic therapy in model tumor systems revealed a complex pattern of changes in targeted tracer accumulation in tumor, which reflects drug-induced tumor regression followed by vascular rebound.
References
More filters
Journal ArticleDOI
VEGF and the quest for tumour angiogenesis factors.
TL;DR: The ability of tumours to induce new blood-vessel formation has been a major focus of cancer research over the past few decades, and vascular endothelial growth factor (VEGF) is now known to be central to this process.
Journal Article
Selective events in the metastatic process defined by analysis of the sequential dissemination of subpopulations of a mouse mammary tumor.
TL;DR: A panel of 5 subpopulations is evaluated that identifies different points of selective failure in tumor cell dissemination and should be valuable in the assessment of antimetastatic therapies.
Journal Article
PTK787/ZK 222584, a Novel and Potent Inhibitor of Vascular Endothelial Growth Factor Receptor Tyrosine Kinases, Impairs Vascular Endothelial Growth Factor-induced Responses and Tumor Growth after Oral Administration
J.M. Wood,G. Bold,Elisabeth Buchdunger,Robert Cozens,Stefano Ferrari,J. Frei,Francesco Hofmann,J. Mestan,Helmut Mett,Terence O'reilly,E Persohn,Johannes Rösel,Christian Schnell,David R. Stover,Andreas Theuer,H Towbin,F Wenger,Kathie Woods-Cook,Andreas Menrad,Gerhard Siemeister,Michael Schirner,Thierauch Kh,Martin R. Schneider,Joachim Drevs,Georg Martiny-Baron,Frank Totzke +25 more
TL;DR: A novel compound with therapeutic potential for the treatment of solid tumors and other diseases where angiogenesis plays an important role, PTK787/ZK 222584 is very well tolerated and does not impair wound healing.
Journal ArticleDOI
A minimal peptide substrate in biotin holoenzyme synthetase‐catalyzed biotinylation
TL;DR: The 14‐mer peptide efficiently mimics the biotin acceptor function of the much larger protein domain normally recognized by BirA, and is identified as the minimum required sequence for biotinylation.
Journal Article
Antivascular Endothelial Growth Factor Receptor (Fetal Liver Kinase 1) Monoclonal Antibody Inhibits Tumor Angiogenesis and Growth of Several Mouse and Human Tumors
Marie Prewett,James Huber,Yiwen Li,Angel Santiago,William T. O'Connor,Karen King,Jay Overholser,Andrea T. Hooper,Bronislaw Pytowski,Larry Witte,Peter Bohlen,Daniel J. Hicklin +11 more
TL;DR: The conclusion that anti-Flk-1 mAb treatment inhibits tumor growth by suppression of tumor-induced neovascularization is supported and the potential for therapeutic application of anti-VEGF receptor antibody in the treatment of angiogenesis-dependent tumors is demonstrated.